Alzheimer's Disease Therapeutics Market to Grow by USD 5.41 Billion (2024-2028), Novel Biomarker R&D Boosts Growth, with AI Driving Market Transformation - Technavio

NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Report with the AI impact on market trends - The global alzheimer's disease therapeutics market size is estimated to grow by USD 5.41 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  10.03%  during the forecast period. Availability, research, and development of novel biomarkers is driving market growth, with a trend towards emergence of regenerative therapies. However, high cost of therapeutics development  poses a challenge. Key market players include AB Science SA, AbbVie Inc., AgeneBio Inc., Biogen Inc., Cipla Ltd., Curasia Medilab, Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Co., Grifols SA, H Lundbeck AS, Johnson and Johnson, Lifecare Neuro Products Ltd., Lupin Ltd., Novartis AG, Pfizer Inc., Psycogen Captab, Solco Healthcare, Teva Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd..

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF

Market Driver

Alzheimer's disease, a leading cause of dementia among older adults, is a neurodegenerative disorder affecting memory impairment, social skills, and everyday tasks. The Alzheimer's disease therapeutics market is witnessing significant advancements in treatment with the development of Amyloid beta inhibitors like Crenezumab and Tau antibodies. Cholinesterase inhibitors such as Aricept, Exelon, and Razadyne remain the mainstay of therapy. Biological therapies, including Memantine, are also gaining popularity. Drug discovery techniques continue to evolve, with an increasing focus on pipeline drugs. The market is segmented by Drug Class, including cholinesterase inhibitors and biological therapies. Hospitals and hospital pharmacies remain the primary Distribution Channel, but e-commerce platforms and online pharmacies are gaining traction. In 2020, over 6 million Americans, mostly Men and Women aged 65 and above, were diagnosed with Alzheimer's disease, leading to increased prescription rates and disability. With an estimated 15 million Americans projected to have Alzheimer's by 2050, the need for effective treatments is urgent. The market's growth is driven by the increasing number of diagnosed patients, life expectancy, and Medicare beneficiaries. Cognitive assessment systems and smartphone apps are emerging tools for early diagnosis and disease management. The Internet and e-commerce services facilitate access to information and drugs, improving patient care and convenience. The Alzheimer's disease therapeutics market is expected to continue growing, offering opportunities for investors and stakeholders. 

Alzheimer's disease is a significant cause of dementia among the elderly population, characterized by memory loss. The disease's underlying mechanism is not fully understood, but it is known to involve the abnormal accumulation and aggregation of proteins. Specifically, extracellular plaques form from the amyloid B-peptide, while intracellular neurofibrillary masses accumulate from hyperphosphorylated tau. Despite extensive research worldwide, there is currently no disease-modifying treatment available for Alzheimer's disease. Researchers continue their efforts to find a cure, focusing on neuronal death, synaptic failure, dendritic and axonal atrophy, and progressive loss of cognitive functions. 

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

• Alzheimer's disease, a leading cause of dementia among older adults, presents significant challenges in the therapeutics market. With an estimated 6.2 million diagnosed patients in the US alone, the need for effective treatments is urgent. Current therapies include cholinesterase inhibitors like Aricept and Exelon, and NMDA receptor antagonists such as Memantine. Amyloid beta inhibitors like Crenezumab are in the pipeline. Drug discovery techniques and biological therapies targeting brain cells and tau protein are under investigation. Cognitive assessment systems aid in early diagnosis. E-Commerce platforms and online pharmacies facilitate access to drugs like Razadyne and Cogentin for Medicare beneficiaries. The market faces challenges in addressing memory impairment, thinking skills, and social skills disability. Life expectancy increases, leading to a larger patient base. The market includes hospitals, hospital pharmacies, and e-commerce services. Men and Women are equally affected, with Alzheimer's being one of the top causes of death among them. The market growth is driven by the increasing prescription rate and the need for effective treatments for Neurodegenerative diseases.
• The Alzheimer's disease therapeutics market is significant due to the increasing prevalence of this debilitating condition. Currently, available treatments only manage symptoms, making the need for disease-modifying therapies more pressing. Researchers are actively developing such therapies, but the high development costs, estimated at around USD5.6 billion, and the lengthy process, spanning approximately 13 years from preclinical studies to US FDA approval, pose challenges. Despite these hurdles, the market continues to advance, driven by the urgent demand for effective Alzheimer's disease treatments.

Discover how AI is revolutionizing market trends- Get your access now!

This alzheimer's disease therapeutics market report extensively covers market segmentation by  

1. Distribution Channel
• 1.1 Hospital pharmacy
• 1.2 Retail pharmacy
• 1.3 E-commerce pharmacy
2. Drug Class
• 2.1 Cholinesterase inhibitors
• 2.2 N-methyl-D-aspartate receptor antagonist
• 2.3 Others
3. Geography 
• 3.1 North America
• 3.2 Europe
• 3.3 Asia
• 3.4 Rest of World (ROW)

1.1 Hospital pharmacy-  The hospital pharmacy segment of the Alzheimer's disease therapeutics market is experiencing significant growth due to the increased demand for these drugs in hospitals. With the expanding healthcare infrastructure in countries like India and China, driven by government investments, the need for Alzheimer's disease therapeutics in hospitals is increasing. The rising number of Alzheimer's disease cases globally is also contributing to this trend. Hospitals are major distribution channels for these therapeutics due to the large-scale requirements of patients undergoing treatment. This growth is expected to continue during the forecast period.

Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

The Alzheimer's disease therapeutics market encompasses innovative treatments for neurodegenerative diseases, primarily Alzheimer's and dementias. Two major categories are Amyloid beta inhibitors and biological therapies. These treatments aim to slow down the progression of these conditions by targeting the root causes, such as the buildup of amyloid beta proteins in the brain. The market caters to both men and women, with increasing prevalence due to aging populations and longer life expectancies. Prescription rates for these therapies are rising, with significant demand in clinics, hospitals, and Medicare beneficiaries. Cognitive assessment systems play a crucial role in diagnosing and monitoring the effectiveness of these treatments, focusing on impairments in thinking, behavioral skills, memory, and everyday tasks. Brain cells are essential in these conditions, and the ultimate goal of Alzheimer's disease therapeutics is to preserve and enhance their function.

Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory impairment, cognitive decline, and disability in everyday tasks. According to the National Institute on Aging, an estimated 6.2 million Americans are currently living with Alzheimer's dementia, with that number projected to increase to nearly 13 million by 2050. Advancements in treatment for Alzheimer's disease have focused on various approaches, including cholinesterase inhibitors such as Aricept and Exelon, and Amyloid beta inhibitors like Crenezumab. Biological therapies, such as Tau antibodies, are also being explored. Cognitive assessment systems and e-commerce platforms, including online pharmacies, are essential for facilitating access to these treatments for diagnosed patients. The drug discovery process continues to evolve with the use of advanced techniques and the pipeline for new drugs. The distribution channel for these therapeutics includes hospitals, hospital pharmacies, and retail pharmacies, with Medicare beneficiaries representing a significant portion of the market. The increasing use of smartphones and the internet has also expanded access to information and services related to Alzheimer's disease, including cognitive assessments and e-commerce services. Despite these advancements, Alzheimer's disease remains a leading cause of death and disability among older adults, particularly among Men and Women, and is one of the most common types of dementia. The global Alzheimer's disease therapeutics market is expected to grow significantly due to the increasing prevalence of the disease and the development of new treatments.

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

• Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• E-commerce Pharmacy
• Drug Class
• Cholinesterase Inhibitors
• N-methyl-D-aspartate Receptor Antagonist
• Others
• Geography
• North America
• Europe
• Asia
• Rest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio